| pubmed-article:8856622 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C0036751 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C0597357 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C0061851 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C0751152 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C1879746 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C1547011 | lld:lifeskim |
| pubmed-article:8856622 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:8856622 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:8856622 | pubmed:dateCreated | 1997-5-22 | lld:pubmed |
| pubmed-article:8856622 | pubmed:abstractText | To study the efficacy of 5-hydroxytryptamine type 3 receptor (5-HT-3R) antagonist (ondansetron) vs paracetamol in primary fibromyalgia (FM) syndrome. | lld:pubmed |
| pubmed-article:8856622 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8856622 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8856622 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8856622 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8856622 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8856622 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8856622 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8856622 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:8856622 | pubmed:issn | 0315-162X | lld:pubmed |
| pubmed-article:8856622 | pubmed:author | pubmed-author:MüllerWW | lld:pubmed |
| pubmed-article:8856622 | pubmed:author | pubmed-author:StrateCC | lld:pubmed |
| pubmed-article:8856622 | pubmed:author | pubmed-author:MennetPP | lld:pubmed |
| pubmed-article:8856622 | pubmed:author | pubmed-author:HrycajPP | lld:pubmed |
| pubmed-article:8856622 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8856622 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:8856622 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8856622 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8856622 | pubmed:pagination | 1418-23 | lld:pubmed |
| pubmed-article:8856622 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:meshHeading | pubmed-meshheading:8856622-... | lld:pubmed |
| pubmed-article:8856622 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8856622 | pubmed:articleTitle | Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome--a preliminary study. | lld:pubmed |
| pubmed-article:8856622 | pubmed:affiliation | Hochrhein Institute for Rehabilitation Research, Bad Säckingen, Germany/Rheinfelden, Switzerland. | lld:pubmed |
| pubmed-article:8856622 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8856622 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8856622 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8856622 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| pubmed-article:8856622 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8856622 | lld:pubmed |
